YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
PD-1 and PD-L1 antibodies have brought about extraordinary clinical benefits for cancer patients, and their indications are expanding incessantly. Currently, most PD-1/PD-L1 agents are administered intravenously, which may be uncomfortable for some cancer patients. Herein, we develop a novel oral-de...
保存先:
主要な著者: | , , , , , , , , , , |
---|---|
フォーマット: | 図書 |
出版事項: |
Elsevier,
2022-06-01T00:00:00Z.
|
主題: | |
オンライン・アクセス: | Connect to this object online. |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
インターネット
Connect to this object online.3rd Floor Main Library
請求記号: |
A1234.567 |
---|---|
所蔵 1 | 利用可 |